Antiviral Drugs - Bhutan

Bhutan

The Antiviral Drugs market in Bhutan is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is set to reach US$252.30k by 2024.
Furthermore, it is anticipated that the market will exhibit a compound annual growth rate (CAGR) of 1.56% from 2024 to 2029, resulting in a market volume of US$272.60k by the end of 2029.
When comparing the global market, it is worth noting that United States is expected to generate the highest revenue in the Antiviral Drugs market, with a projected amount of US$30,640.00m in 2024.
Bhutan's pharmaceutical market for antiviral drugs is experiencing a surge in demand due to the country's focus on maintaining a healthy population amidst the ongoing pandemic.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have been in high demand in Bhutan in recent years due to the increasing prevalence of viral infections.

Customer preferences: Bhutanese customers prefer antiviral drugs that are effective against a wide range of viruses and have minimal side effects. They also prefer drugs that are affordable and easily accessible.

Trends in the market: The antiviral drugs market in Bhutan has been experiencing steady growth due to the increasing incidence of viral infections such as influenza, hepatitis, and HIV. The market has also been driven by the growing awareness of the benefits of antiviral drugs in treating and preventing viral infections. In addition, the government's efforts to improve healthcare infrastructure and increase access to essential medicines have contributed to the growth of the market.

Local special circumstances: Bhutan has a small population and limited healthcare infrastructure, which presents unique challenges for the antiviral drugs market. The government has been working to address these challenges by investing in healthcare infrastructure and increasing access to essential medicines. However, there is still a need for greater awareness about the benefits of antiviral drugs and their availability in the market.

Underlying macroeconomic factors: Bhutan's economy has been growing steadily in recent years, driven by the hydropower sector and tourism. This has led to an increase in disposable income and a growing middle class, which has contributed to the growth of the antiviral drugs market. However, the country's small population and limited healthcare infrastructure present challenges for the market, and there is a need for continued investment in healthcare infrastructure and greater awareness about the benefits of antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.